CAP 256 team visits VRC

30 April 2017

Professor Lynn Morris, CAPRISA Research Associate and head of the HIV Virology section in the Center for HIV and STIs at the National Institutes of Communicable Diseases in South Africa recently visited the NIH Vaccine Research Center’s (VRC) Gaithersburg process plant as well as the Frederick pilot plant where the manufacture of the CAP256-VRC26.25 antibody for human clinical trials is underway. Prof Morris gave a research seminar at the VRC where she discussed the history of the CAP256 donor and various studies on the isolated antibodies as well as the plans for the upcoming clinical trials.